These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32656071)

  • 1. A 3-MicroRNA Signature Identified From Serum Predicts Clinical Outcome of the Locally Advanced Gastric Cancer.
    Chen S; Lao J; Geng Q; Zhang J; Wu A; Xu D
    Front Oncol; 2020; 10():565. PubMed ID: 32656071
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
    Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
    Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
    Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
    Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 7. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a novel miRNA classifier as a prognostic signature for stage II/III colorectal cancer.
    Feng J; Wei Q; Yang M; Wang X; Liu B; Li J
    Ann Transl Med; 2021 May; 9(9):747. PubMed ID: 34268360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.
    Jacob H; Stanisavljevic L; Storli KE; Hestetun KE; Dahl O; Myklebust MP
    Oncotarget; 2017 Oct; 8(50):87837-87847. PubMed ID: 29152124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
    Hess J; Unger K; Maihoefer C; Schüttrumpf L; Wintergerst L; Heider T; Weber P; Marschner S; Braselmann H; Samaga D; Kuger S; Pflugradt U; Baumeister P; Walch A; Woischke C; Kirchner T; Werner M; Werner K; Baumann M; Budach V; Combs SE; Debus J; Grosu AL; Krause M; Linge A; Rödel C; Stuschke M; Zips D; Zitzelsberger H; Ganswindt U; Henke M; Belka C
    Clin Cancer Res; 2019 Mar; 25(5):1505-1516. PubMed ID: 30171046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients.
    Lu JH; Zuo ZX; Wang W; Zhao Q; Qiu MZ; Luo HY; Chen ZH; Mo HY; Wang F; Yang DD; Wang Y; Wei XL; Wu QN; Ju HQ; Xu RH; Zeng ZL
    Cell Death Discov; 2018; 4():116. PubMed ID: 30588338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying a new microRNA signature as a prognostic biomarker in colon cancer.
    Lv Y; Duanmu J; Fu X; Li T; Jiang Q
    PLoS One; 2020; 15(2):e0228575. PubMed ID: 32049961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microRNA survival signature (MiSS) for advanced ovarian cancer.
    Shih KK; Qin LX; Tanner EJ; Zhou Q; Bisogna M; Dao F; Olvera N; Viale A; Barakat RR; Levine DA
    Gynecol Oncol; 2011 Jun; 121(3):444-50. PubMed ID: 21354599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer.
    Liu X; Zhang X; Zhang Z; Chang J; Wang Z; Wu Z; Wang C; Sun Z; Ge X; Geng R; Tang W; Dai C; Lin Y; Lin F; Sun M; Jia W; Xue W; Ji J; Hu Y; Qin G; Li J
    Int J Cancer; 2017 Nov; 141(10):2093-2102. PubMed ID: 28722210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum miR-626 and miR-5100 are Promising Prognosis Predictors for Oral Squamous Cell Carcinoma.
    Shi J; Bao X; Liu Z; Zhang Z; Chen W; Xu Q
    Theranostics; 2019; 9(4):920-931. PubMed ID: 30867806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W; Zeng X; Li N; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
    Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
    J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.